Panitumumab (Vectibix®) is a recombinant, human monoclonal antibody
that binds to the human epidermal growth factor receptor (EGFR) and is
approved by the US FDA for the treatment of carcinomas of the colon and
rectum. Panitumumab competitively inhibits the binding of ligands for
EGFR, inhibiting cell growth, induction of apoptosis, and decreased
pro-inflammatory cytokine and vascular growth factor production.
Panitumumab is indicated for for the treatment of EGFR-expressing,
metastatic colorectal carcinoma with disease progression on or
following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing
chemotherapy regimens.
In clinical trials, panitumumab caused skin, ocular and mucosal related
toxicities in 90% of treated patients. Consequences of the severe
dermatologic toxicities included infection complicated by sepsis, septic
death, and abscess formation requiring incisions and drainage.
treatment of EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
| Source | Link | Revision Date | Access Date |
| Vectibix Prescribing Information | http://www.amgen.com/medpro/vectibix_pi.html | 2007-October | 2008-June-03 |
| NCI Cancer Topics - FDA Approval for Panitumumab | http://www.cancer.gov/cancertopics/d...da-panitumumab | 2008-May-22 | |
|
Gibson TB, Ranganathan A, Grothey A Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clinical colorectal cancer 2006 May;6(1):29-31 | http://www.ncbi.nlm.nih.gov/pubmed/16796788 | 2008-May-22 |
NO RELIANCE FOR MEDICAL DECISIONSInformation, services and/or other features contained in this web site (including any electronic bulletin board contained therein) are being provided for general educational and informational purposes only and are not intended to be a substitute for independent medical judgment or constitute case-specific medical advice or treatment in any way. Such information, services and/or features are not intended to serve as the primary basis for making personal or professional medical decisions, nor are they intended to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to making any treatment or diagnosis decisions and with any questions you may have regarding a medical condition or its diagnosis or treatment. You should confirm any information obtained from this site with other sources before undertaking any treatment or otherwise taking any actions relating thereto. Any reliance on any information, services or other features contained in this site is solely at your own risk. |
|
Clinical Immunology Society 555 East Wells Street, Suite 1100 Milwaukee, WI 53202-3823 USA Phone: 414/224-8095 | Fax: 414/272-6070 Email: info@clinimmsoc.org © 2001-2008 Clinical Immunology Society | Web Site Disclaimer |
